Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesTeva Comments On Positive Results Of Phase III Trial In Mediwound's Debrase
Teva Pharmaceutical Industries, 10/21/09
Teva Pharmaceutical Industries Ltd. announced that MediWound Ltd., a company in which Teva holds an 11% interest, reported positive results from a pre planned interim analysis of a phase III trial for Debrase, an enzymatic debriding agent for burns. MediWound reported that the phase III study with Debrase for the treatment of burns met the two primary endpoints of the study reduction in the percentage of wound surgically excised and reduction in the percentage of wound autografted with statistical significance.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study
Alimentary Pharmacology and Therapeutics, 12/04/09
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials
BMC Infectious Diseases, 12/03/09
Sponsor
Article Search
Sponsor